The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of vascular smooth muscle cell proliferation. Specifically, a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-I receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG or a fragment thereof is provided for use in the treatment of vascular smooth muscle (VSM) cell proliferation.